Novo Nordisk (NVO) valuation

Run six valuation models on Novo Nordisk with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

NVO
NVO

Novo Nordisk

NVO · Healthcare

Current price

40,63 USD

𝕏 Share on X
You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
179.05 B DKK
PE (TTM | NTM | +1y)
10.26 | 11.57 | 1.74
Price / Sales
0.54
EV / EBITDA
1.50
Price / Book
5.47

Cash flow

FCF yield(9.83 / 40.63)
+24.19%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
+33.92%
Operating margin
+50.78%
Quarterly earnings (YoY)
-16.33%
Quarterly revenue (YoY)
+5.63%

Balance

Cash
46.35 B DKK
Debt
134.48 B DKK
Net position
-88.13 B DKK

Dividend

Dividend yield
+4.32%
Payout ratio
+45.36%
Next payout
8/25/2026

Price (5 years)

-28.57%
142.88 DKK

What the market paid for its earnings

P/E (TTM)10.8×
204060Its own median 22.5×Its own mean 29.7×20212026

Each week's price divided by the earnings per share already reported by that date — four quarters where a company reports them, its last full year otherwise. Loss-making weeks are not drawn. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What the market paid for the year ahead

Forward P/E11.6×
10203040Its own median 21.4×Its own mean 23.0×20212026

Each week's price divided by the earnings of the year still ahead of it. Those years have since happened, so this is the multiple paid against the figure that landed: nobody records what analysts expected at the time. The most recent stretch uses today's consensus. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What analysts expect

Consensus revenue and earnings per share for the periods not yet reported.

Revenue forecast

ReportedEstimate
025B50B75BQ4 25: 79.14 B DKKQ4 25Q1 26: 96.82 B DKKQ1 26Q2 26: 78.49 B DKKQ2 26Q3 26: 79.20 B DKKQ3 26Q4 26 · Estimate: 79.58 B DKK (72.18 B DKK – 83.18 B DKK)Q4 26Q1 27 · Estimate: 73.29 B DKK (73.29 B DKK – 73.29 B DKK)Q1 27DKK

Consensus of 8 analysts for Q4 26 · +0.55% year on year

EPS forecast

ReportedEstimate
0246Q4 25: 6.04 · expected 5.90 (+2.34%)Q4 25Q1 26: 6.63 · expected 6.96 (-4.75%)Q1 26Q2 26: 6.18 · expected 4.98 (+24.01%)Q2 26Q3 26: 5.79 · expected 4.62 (+25.31%)Q3 26Q4 26 · Estimate: 0.73 (0.69 – 0.78)Q4 26Q1 27 · Estimate: 0.87 (0.87 – 0.87)Q1 27

Consensus of 3 analysts for Q4 26 · -19.3% year on year · adjusted earnings

Analyst consensus from Yahoo Finance. The dashed bar is the average and the whisker runs from the lowest analyst to the highest. On periods already reported, the green or red line marks what had been expected: below the bar means the company beat it. EPS is measured on an adjusted basis, which is what analysts forecast against and is not the accounting profit in the statements.

Revenue

estimate
025B50B75BQ3 25: 74.98 B DKKQ3 25Q4 25: 79.14 B DKKQ4 25Q1 26: 96.82 B DKKQ1 26Q2 26: 78.49 B DKKQ2 26Q3 26: 79.20 B DKKQ3 26Q4 26 · estimate: 79.58 B DKKQ4 26DKK

EBITDA

020B40B60BQ3 25: 31.44 B DKKQ3 25Q4 25: 31.74 B DKKQ4 25Q1 26: 69.21 B DKKQ1 26Q2 26: 28.38 B DKKQ2 26Q3 26: 37.38 B DKKQ3 26DKK

Net income

020B40BQ3 25: 20.01 B DKKQ3 25Q4 25: 26.89 B DKKQ4 25Q1 26: 48.56 B DKKQ1 26Q2 26: 20.99 B DKKQ2 26Q3 26: 16.74 B DKKQ3 26DKK

Free cash flow

-20B020B40BQ3 25: 30.85 B DKKQ3 25Q4 25: -37.51 B DKKQ4 25Q1 26: 12.05 B DKKQ1 26Q2 26: 42.40 B DKKQ2 26Q3 26: 28.03 B DKKQ3 26DKK

EPS

0510Q3 25: 4.50Q3 25Q4 25: 6.04Q4 25Q1 26: 10.91Q1 26Q2 26: 4.74Q2 26Q3 26: 3.79Q3 26

Cash & debt

CashDebt
050B100BQ4 14 · Cash: 13.68 B DKKQ4 14Q4 15 · Cash: 15.85 B DKKQ4 16 · Cash: 18.46 B DKKQ4 17 · Cash: 17.16 B DKKQ4 17Q4 18 · Cash: 15.63 B DKKQ4 19 · Cash: 15.41 B DKKQ4 20 · Cash: 12.23 B DKKQ4 20Q4 21 · Cash: 10.72 B DKKQ4 22 · Cash: 12.65 B DKKQ4 23 · Cash: 14.39 B DKKQ4 23Q3 25 · Cash: 32.08 B DKKQ3 25 · Debt: 101.21 B DKKQ4 25 · Cash: 26.46 B DKKQ4 25 · Debt: 130.96 B DKKQ1 26 · Cash: 21.13 B DKKQ1 26 · Debt: 146.38 B DKKQ1 26Q2 26 · Cash: 44.48 B DKKQ2 26 · Debt: 140.13 B DKKQ3 26 · Cash: 44.15 B DKKQ3 26 · Debt: 134.48 B DKKQ3 26DKK

Return of capital

DividendsBuybacks
010B20B30BQ3 25 · Dividends: 16.66 B DKKQ3 25Q1 26 · Dividends: 35.31 B DKKQ1 26 · Buybacks: 2.40 B DKKQ1 26Q2 26 · Buybacks: 3.50 B DKKQ2 26Q3 26 · Dividends: 16.58 B DKKQ3 26 · Buybacks: 4.10 B DKKQ3 26DKK

Operating expenses

R&DSG&A
010B20B30BQ3 25 · R&D: 15.39 B DKKQ3 25 · SG&A: 17.88 B DKKQ3 25Q4 25 · R&D: 14.65 B DKKQ4 25 · SG&A: 17.44 B DKKQ4 25Q1 26 · R&D: 10.28 B DKKQ1 26 · SG&A: 13.22 B DKKQ1 26Q2 26 · R&D: 17.79 B DKKQ2 26 · SG&A: 16.31 B DKKQ2 26Q3 26 · R&D: 19.90 B DKKQ3 26 · SG&A: 16.26 B DKKQ3 26DKK

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Popular companies